|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ryan DP, Hong TS and Bardeesy N:
Pancreatic adenocarcinoma. N Engl J Med. 371:1039–1049. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Orang Valinezhad A, Safaralizadeh R and
Kazemzadeh-Bavili M: Mechanisms of miRNA-mediated gene regulation
from common downregulation to mRNA-specific upregulation. Int J
Genomics. 2014:9706072014.PubMed/NCBI
|
|
4
|
Bushati N and Cohen SM: microRNA
functions. Annu Rev Cell Dev Biol. 23:175–205. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hwang HW and Mendell JT: MicroRNAs in cell
proliferation, cell death, and tumorigenesis. Br J Cancer. Suppl
96:R40–R44. 2007.PubMed/NCBI
|
|
6
|
Kwak PB, Iwasaki S and Tomari Y: The
microRNA pathway and cancer. Cancer Sci. 101:2309–2315. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang S, Liu X, Liu J, Guo H, Xu H and
Zhang G: PGC-1 alpha interacts with microRNA-217 to functionally
regulate breast cancer cell proliferation. Biomed Pharmacother.
85:541–548. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yates LA, Norbury CJ and Gilbert RJ: The
long and short of microRNA. Cell. 153:516–519. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cioffi M, Trabulo SM, Sanchez-Ripoll Y,
Miranda-Lorenzo I, Lonardo E, Dorado J, Vieira Reis C, Ramirez JC,
Hidalgo M, Aicher A, et al: The miR-17-92 cluster counteracts
quiescence and chemoresistance in a distinct subpopulation of
pancreatic cancer stem cells. Gut. 64:1936–1948. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Neesse A and Gress TM: Emerging role of
microRNAs to tackle drug resistance in pancreatic cancer. Gut.
64:1842–1843. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li J, Li D and Zhang W: Tumor suppressor
role of miR-217 in human epithelial ovarian cancer by targeting
IGF1R. Oncol Rep. 35:1671–1679. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wei R, Deng Z and Su J: miR-217 targeting
Wnt5a in osteosarcoma functions as a potential tumor suppressor.
Biomed Pharmacother. 72:158–164. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Su J, Wang Q, Liu Y and Zhong M: miR-217
inhibits invasion of hepatocellular carcinoma cells through direct
suppression of E2F3. Mol Cell Biochem. 392:289–296. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao WG, Yu SN, Lu ZH, Ma YH, Gu YM and
Chen J: The miR-217 microRNA functions as a potential tumor
suppressor in pancreatic ductal adenocarcinoma by targeting KRAS.
Carcinogenesis. 31:1726–1733. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Guo J, Feng Z, Huang Z, Wang H and Lu W:
MicroRNA-217 functions as a tumour suppressor gene and correlates
with cell resistance to cisplatin in lung cancer. Mol Cells.
37:664–671. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang B, Shen ZL, Jiang KW, Zhao G, Wang
CY, Yan YC, Yang Y, Zhang JZ, Shen C, Gao ZD, et al: MicroRNA-217
functions as a prognosis predictor and inhibits colorectal cancer
cell proliferation and invasion via an AEG-1 dependent mechanism.
BMC Cancer. 15:4372015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang Q, Yuan Y, Cui J, Xiao T and Jiang
D: miR-217 promotes tumor proliferation in breast cancer via
targeting DACH1. J Cancer. 6:184–191. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Byrne JA, Balleine RL, Fejzo Schoenberg M,
Mercieca J, Chiew YE, Livnat Y, St Heaps L, Peters GB, Byth K,
Karlan BY, et al: Tumor protein D52 (TPD52) is overexpressed and a
gene amplification target in ovarian cancer. Int J Cancer.
117:1049–1054. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rubin MA, Varambally S, Beroukhim R,
Tomlins SA, Rhodes DR, Paris PL, Hofer MD, Storz-Schweizer M,
Kuefer R, Fletcher JA, et al: Overexpression, amplification, and
androgen regulation of TPD52 in prostate cancer. Cancer Res.
64:3814–3822. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhu H, Lam DC, Han KC, Tin VP, Suen WS,
Wang E, Lam WK, Cai WW, Chung LP and Wong MP: High resolution
analysis of genomic aberrations by metaphase and array comparative
genomic hybridization identifies candidate tumour genes in lung
cancer cell lines. Cancer Lett. 245:303–314. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Byrne JA, Mattei MG and Basset P:
Definition of the tumor protein D52 (TPD52) gene family
through cloning of D52 homologues in human (hD53) and
mouse (mD52). Genomics. 35:523–532. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Queiroz KC, Shi K, Duitman J, Aberson HL,
Wilmink JW, van Noesel CJ, Richel DJ and Spek CA:
Protease-activated receptor-1 drives pancreatic cancer progression
and chemoresistance. Int J Cancer. 135:2294–2304. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lin C, von der Thüsen J, Daalhuisen J, ten
Brink M, Crestani B, van der Poll T, Borensztajn K and Spek CA:
Pharmacological targeting of protease-activated receptor 2 affords
protection from bleomycin-induced pulmonary fibrosis. Mol Med.
21:576–583. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chang W, Liu M, Xu J, Fu H, Zhou B, Yuan T
and Chen P: MiR-377 inhibits the proliferation of pancreatic cancer
by targeting Pim-3. Tumour Biol. 37:14813–14824. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yonemori K, Kurahara H, Maemura K and
Natsugoe S: MicroRNA in pancreatic cancer. J Hum Genet. 62:33–40.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Slattery ML, Lundgreen A, Herrick JS, Caan
BJ, Potter JD and Wolff RK: Associations between genetic variation
in RUNX1, RUNX2, RUNX3, MAPK1 and eIF4E and risk of
colon and rectal cancer: Additional support for a TGF-β-signaling
pathway. Carcinogenesis. 32:318–326. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nathan N, Keppler-Noreuil KM, Biesecker
LG, Moss J and Darling TN: Mosaic disorders of the
PI3K/PTEN/AKT/TSC/mTORC1 signaling pathway. Dermatol Clin.
35:51–60. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Samuels Y and Velculescu VE: Oncogenic
mutations of PIK3CA in human cancers. Cell Cycle. 3:1221–1224.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hennessy BT, Smith DL, Ram PT, Lu Y and
Mills GB: Exploiting the PI3K/AKT pathway for cancer drug
discovery. Nat Rev Drug Discov. 4:988–1004. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhao L and Vogt PK: Class I PI3K in
oncogenic cellular transformation. Oncogene. 27:5486–5496. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fleisher B, Clarke C and Ait-Oudhia S:
Current advances in biomarkers for targeted therapy in
triple-negative breast cancer. Breast Cancer. 8:183–197.
2016.PubMed/NCBI
|
